Mepolizumab is a humanized monoclonal antibody against IL‐5, used to treat EGPA and asthma by inhibiting eosinophil proliferation and activity, consequently reducing airway inflammation and EGPA symptoms. Here, IL5 is linked to eosinophilic granulomatosis with polyangiitis.